Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>UBS Envisions INNOVENT BIO's Partnership with Eli Lilly to Provide Upside for Drug Advancement Targets
Recommend 3 Positive 5 Negative 1 |
||||
|
||||
|
INNOVENT BIO (01801.HK) and Eli Lilly and Company (LLY.US) have entered into a collaboration on multiple early-stage oncology and immunology assets, according to a UBS research report. The agreement includes an upfront payment of USD350 million, potential milestone payments up to USD8.5 billion, and tiered royalties based on net sales. UBS not only favored the seventh collaboration between the two companies, but it also saw this collaboration as a new model of partnership compared to previous out-licensing deals, as it involves the establishment of a new company and joint development. More importantly, UBS observed that the potential assets include new ones not previously seen in INNOVENT BIO's R&D pipeline, which could provide upside potential for the company's original guidance to advance 8-10 candidate drugs into clinical stages every year. UBS has given INNOVENT BIO a target price of HKD137.4 and a Buy rating. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
